CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral

Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen

In the news release, "ArcStone Securities and Investments Corp. serves as exclusive financial advisor to Mangoceuticals Inc." issued on 25-Apr-2025 by ArcStone over Newsfile, the company has advised that the main heading should not have included "acquisition of Smokeless Technology Corp." The complete, corrected release follows:

Transaction Adds Executive Bench Strength, IP and Launches New Business Vertical for Mangoceuticals in Lucrative Oral Stimulant Pouch Segment on the Heels of the Significant Success of Turning Point Brands and Philip Morris International

New York, New York and Dallas, Texas--(Newsfile Corp. - April 26, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a cross-border financial services firm, is pleased to announce its role as exclusive financial advisor to Mangoceuticals Inc. (NASDAQ: MGRX) ("Mangoceuticals") in its acquisition of IP, assets and technology from Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based innovator and disruptor in stimulant-based pouches and functional wellness delivery systems.

This transaction marks ArcStone's strategic M&A advisory expertise advising a NASDAQ-listed acquirer and a privately held international company, underscoring the strength of its cross-border platform and domain expertise in health and wellness categories. The acquisition provides Mangoceuticals Inc. with the foundation to launch high impact pouches for the consumer-packaged goods sector and attack multiple verticals from athletes to fitness enthusiasts to Gen Z's seeking healthier alternatives to mainstream nicotine pouches. In addition, it will be one of the few high torque small cap pouch investments available with a strong executive bench that includes 20+ years at Fortune 150 companies with a Nasdaq public equity currency for future M&A. This transaction significantly enhances MGRX's positioning across retail and institutional capital markets.

"Having worked with several large tobacco and wellness companies since co-founding the cannabis practice at Bank of Montreal in 2017, I can confidently say that the pouch format is one of the most scalable, investable platforms we've seen," said Michael Astone, CEO of ArcStone. "This transaction positions Mangoceuticals with the public currency, executive leadership, and patent-protected science to lead the next wave of consolidation and innovation in functional pouches."